Primary hormone therapy for locally advanced prostate cancer

被引：1
作者：
Swanson G.P. [1 ]
机构：
[1] University of Texas Health Science Center, San Antonio, MC 7889, San Antonio, TX 78229
来源：
Current Urology Reports | 2006年 / 7卷 / 3期
关键词：
Prostate Cancer; Radical Prostatectomy; Radiation Therapy Oncology Group; Advanced Prostate Cancer; Goserelin;
D O I：
10.1007/s11934-006-0025-x
中图分类号：
学科分类号：
摘要：
Locally advanced prostate cancer is a treatment dilemma. As with prostate cancer in general, there is no clear evidence that aggressive intervention (ie, surgery or radiation) is superior to noninvasive interventions (eg, delayed treatment or androgen ablation). Because patients with locally advanced prostate cancer have a high risk of local and systemic recurrence, there is some argument to proceed with androgen ablation as the sole modality of treatment. The data using this approach are limited, but an understanding of the degree and duration of response is helpful in selecting patients for primary androgen ablation. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：225 / 232
页数：7
相关论文
共 40 条
  • [1] Walsh P.C., DeWeese T.L., Eisenberger M.A., A structured debate: Immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment, J Urol, 166, pp. 508-516, (2001)
  • [2] Whitmore W.F., Hormone therapy in prostatic cancer, Am J Med, 21, pp. 697-712, (1956)
  • [3] Huggins C., Hodges C.V., Studies on prostate cancer: The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res, 1, pp. 292-297, (1941)
  • [4] D'Amico A.V., Whittington R., Malkowicz S.B., Et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, pp. 969-974, (1998)
  • [5] Zelefsky M.J., Fuks Z., Hunt M., Et al., High-dose radiation delivered by intensity-modulated conformal radiotherapy improves the outcome of localized prostate cancer, J Urol, 166, pp. 876-881, (2001)
  • [6] Nesbit R.M., Baum W.C., Endocrine control of prostatic carcinoma: Clinical and statistical survey of 1818 cases, J Am Med Assoc, 143, pp. 1317-1320, (1950)
  • [7] Emmett J.L., Greene L.F., Papantoniou A., Endocrine therapy in carcinoma of the prostate gland: 10-Year survival studies, J Urol, 83, pp. 471-484, (1960)
  • [8] Lepor H., Ross A., Walsh P., The influence of hormonal therapy on survival of men with advanced prostatic cancer, J Urol, 128, pp. 335-340, (1982)
  • [9] Byar D.P., Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate, Cancer, 32, pp. 1126-1130, (1973)
  • [10] Blackard C.E., Byar D.P., Jordon W.P., Orchiectomy for advanced prostatic carcinoma: A re-evaluation, Urology, 1, (1973)
1234